Search results for "INJECTION"

showing 10 items of 920 documents

Report of results obtained in 2,934 women using donor sperm: donor insemination versus in vitro fertilization according to indication.

2011

Objective To demonstrate that the use of donor sperm leads to varying outcome rates and that its use has evolved. Design Retrospective observational cohort study. Setting University-affiliated private IVF setting. Patient(s) Women (2,934) undergoing donor insemination (DI) or IVF with donor sperm (IVF-D). Intervention(s) None. Main Outcome Measurement(s) We evaluated the distribution of the clinical indications for the use of donated sperm, studying the reproductive outcome. Result(s) A total of 1,663 DI (57%) and 1,271 IVF-D (43%) were performed. There were significant differences in the indications for the use of donated sperm (DI vs. IVF-D). Regarding pregnancy rates (PR), cases of nonob…

AdultMalemedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentPopulationFertilization in VitroBiologyRisk AssessmentIntracytoplasmic sperm injectionPregnancyRisk FactorsmedicineOdds RatioHumansAdvanced maternal ageSperm Injections Intracytoplasmiceducationreproductive and urinary physiologyAzoospermiaRetrospective StudiesGynecologyPregnancyeducation.field_of_studyIn vitro fertilisationChi-Square Distributionurogenital systemObstetricsObstetrics and GynecologySingle Personmedicine.diseaseSpermSpermatozoaTissue DonorsLogistic ModelsTreatment OutcomeReproductive MedicineSpainInsemination Artificial HeterologousFemaleDonor spermCohort studyMaternal AgeFertility and sterility
researchProduct

Outcome of intracytoplasmic sperm injection with and without polar body diagnosis of oocytes.

2008

Objective To compare the reproductive outcome of women undergoing intracytoplasmic sperm injection (ICSI) with or without polar body diagnosis of oocytes. Design Nonrandomized retrospective study. Setting University-based human genetic institute in collaboration with a private fertility center. Patient(s) Six hundred seven women undergoing ICSI with polar body diagnosis and 591 women undergoing ICSI without polar body diagnosis at the same time in the same fertility center. Intervention(s) Polar body testing of ICSI oocytes by five-color fluorescence in situ hybridization. Main Outcome Measure(s) Pregnancy rate (positive fetal heartbeats) and live-birth rate (of at least one child). Result(…

AdultMalemedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentmedia_common.quotation_subjectAneuploidyFertilityFertilization in VitroIntracytoplasmic sperm injectionPolar bodyAge DistributionPregnancyGermanymedicineHumansSperm Injections Intracytoplasmicreproductive and urinary physiologyZona Pellucidamedia_commonRetrospective StudiesGynecologyPregnancyurogenital systembusiness.industryObstetricsInfant NewbornPregnancy OutcomeObstetrics and GynecologyRetrospective cohort studyFertility Agents FemaleMiddle Agedmedicine.diseaseAneuploidyEmbryo TransferPregnancy rateReproductive Medicineembryonic structuresOocytesGestationFemaleLeuprolidebusinessLive BirthFertility and sterility
researchProduct

Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics

2017

BACKGROUND People with schizophrenia and other severe mental disorders have an increased mortality mainly attributed to natural causes, specifically cardiovascular disease and cancer. The metabolic syndrome and the Framingham Risk Score are epidemiologic tools related to long-term cardiovascular disease risk and they are increased in people with severe mental disorders. This increase has been attributed both to the disorder itself and to the use of antipsychotic drugs. OBJECTIVE To quantify the cardiovascular risk in a group of people treated with long-acting injectable antipsychotics. METHODS This is a cross-sectional study developed in an outpatient mental health clinic in which the preva…

AdultMalemedicine.medical_specialtyPsychosisHealth StatusEndocrinology Diabetes and Metabolismmedicine.medical_treatmentHealth BehaviorDiseasePharmacologyRisk AssessmentSeverity of Illness IndexInjectionsHabitsYoung Adult03 medical and health sciences0302 clinical medicineCost of IllnessRisk FactorsInternal medicinePrevalencemedicineHumansImmunology and AllergyAntipsychoticLife StyleAgedMetabolic SyndromeFramingham Risk Scorebusiness.industryMental DisordersMiddle Agedmedicine.diseaseMental healthObesity030227 psychiatryCross-Sectional StudiesCardiovascular DiseasesSpainSchizophreniaDelayed-Action PreparationsFemaleMetabolic syndromebusiness030217 neurology & neurosurgeryAntipsychotic AgentsEndocrine, Metabolic & Immune Disorders - Drug Targets
researchProduct

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.

2018

Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, in preventing hereditary angioedema attacks.Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites in Canada, Europe, Jordan, and the United States. Patients were randomized between March 3, 2016, and September 9, 2016; last day of follow-up was April 13, 2017. Randomization was 2:1 lanadelumab to placebo; patients assigned to lanadelumab were further randomized 1:1:1 to 1 of the 3 dose regimens. Patients 12 years or older with hereditary a…

AdultMalemedicine.medical_specialtyRandomizationAdolescentInjections SubcutaneousLanadelumabPlaceboAntibodies Monoclonal Humanizedlaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumans030212 general & internal medicineYoung adultAdverse effectChildPlasma KallikreinAgedHereditary Angioedema Types I and IIbusiness.industryAntibodies MonoclonalCorrectionGeneral MedicineMiddle Agedmedicine.diseaseClinical trial030228 respiratory systemHereditary angioedemaQuality of LifeFemalebusinessJAMA
researchProduct

Randomized clinical trial of botulinum toxin injection for pain relief in patients with thrombosed external haemorrhoids

2008

Abstract Background Thrombosed external haemorrhoids are one of the most frequent anorectal emergencies. They are associated with swelling and intense pain. Internal sphincter hypertonicity plays a role in the aetiology of the pain. This study evaluated the efficacy and safety of an intrasphincteric injection of botulinum toxin for pain relief in patients with thrombosed external haemorrhoids. Methods Thirty patients with thrombosed external haemorrhoids who refused surgical operation were randomized into two groups. Patients received an intrasphincteric injection of either 0·6 ml saline or 0·6 ml of a solution containing 30 units botulinum toxin. Anorectal manometry was performed before tr…

AdultMalemedicine.medical_specialtyRandomizationAnal CanalPainInjections IntralesionalHemorrhoidsSeverity of Illness Indexlaw.inventionRandomized controlled triallawmedicineHumansbotulinum toxinBotulinum Toxins Type APain MeasurementAnalgesicsVascular diseasebusiness.industryUrethral sphincterAnorectal manometryThrombosisAnal canalmedicine.diseaseBotulinum toxinSurgeryClinical trialTreatment Outcomemedicine.anatomical_structureNeuromuscular AgentsFemaleSurgerybusinessmedicine.drugBritish Journal of Surgery
researchProduct

A Randomized-Controlled Study of Intrathecal Versus Epidural Thoracic Analgesia in Patients Undergoing Abdominal Cancer Surgery

2008

Background. We sought to determine the effectiveness of continuous intrathecal thoracic analgesia (ITA) in comparison with continuous epidural thoracic analgesia (ETA) for the management of postoperative pain after abdominal cancer surgery in a randomised controlled study. Materials and methods. Catheters were inserted at T8-10 level for both techniques. Sixty patients were randomized to receive ITA providing levobupivacaine 0.25%, at 0.5-0-7 ml/h, associated with a single bolus of morphine 0.15 mg, or ETA with levobupivacaine 0.25% 4-6 ml/h and a single bolus of epidural morphine 2-3 mg. Data were collected before discharging from recovery room to the surgical ward, 1, 2, 3, 8, 12, 24 h, a…

AdultMalemedicine.medical_specialtyResuscitationAdolescentabdominal cancer surgerySettore MED/41 - AnestesiologiaDiuresisHemodynamicsHealth Informaticsepidural analgesiaintrathecal analgesiapostoperative painCritical Care and Intensive Care Medicineintrathecal analgesialaw.inventionYoung AdultRandomized controlled triallawIntensive careAnesthesiologymedicineHumansAnesthetics LocalInjections SpinalAgedPain MeasurementAged 80 and overPain Postoperativebusiness.industryLidocaineepidural analgesiaMiddle AgedSurgeryAnalgesia EpiduralTreatment OutcomeAnesthesiology and Pain MedicineLevobupivacaineAbdominal NeoplasmsAnesthesiaMorphineFemalebusinessmedicine.drugJournal of Clinical Monitoring and Computing
researchProduct

Endovascular therapy for vasospasm after aneurysmatic subarachnoid hemorrhage

2016

Balloon angioplasty and/or selective intra-arterial vasodilator therapies are treatment options in patients with vasospasm after subarachnoid hemorrhage (SAH). We analyzed the effect of balloon angioplasty and/or selective intra-arterial vasodilator therapy in our patients.Twenty-six patients (vasodilation group, VDT) were treated with intra-arterial nimodipine. The balloon angioplasty with nimodiopine-group (BAP-N group) comprised 21 patients. The primary endpoint of this study was successful angiographic vessel dilation in vasospastic vessels after balloon angioplasty, together with nimodipine (BAP-N group), compared to intra-arterial vasodilator therapy (VDT group) with nimodipine alone.…

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageVasodilator Agentsmedicine.medical_treatmentCerebral arteriesVasodilationBalloon030218 nuclear medicine & medical imaging03 medical and health sciencesPostoperative Complications0302 clinical medicineInternal medicineAngioplastymedicineClinical endpointHumansVasospasm IntracranialNimodipineAgedRetrospective Studiesbusiness.industryEndovascular ProceduresVasospasmGeneral MedicineCerebral ArteriesMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseTreatment OutcomeInjections Intra-ArterialAnesthesiaCardiologyFemaleNimodipineSurgeryPatient SafetyNeurology (clinical)businessAngioplasty Balloon030217 neurology & neurosurgerymedicine.drugBritish Journal of Neurosurgery
researchProduct

Sudden Sensorineural Hearing Loss: Results of intratympanic steroids as salvage treatment

2012

Objective: The aim of the present study was to verify the efficacy and the safety of intratympanic dexamethasone to treat sudden sensorineural hearing loss as salvage therapy. Materials and methods: A prospective study was conducted on patients affected by idiopathic sudden hearing loss who were treated before with some systemic therapy, but without recovery of the hearing The patients able to undergo the study, but who refused salvage treatment were considered as control group. A solution of Dexamethasone 4 mg/ml was then injected through the posterior–inferior quadrant filling completely the middle ear. The follow-up in the following 6 months included an audiogram every month. Results: Th…

AdultMalemedicine.medical_specialtyTympanic MembraneAdolescentNeurosensorial Hearing Loss Steroids treatmentHearing lossHearing Loss SensorineuralSalvage therapyInjections IntralesionalAudiologyRisk AssessmentSystemic therapyDexamethasoneYoung AdultConfidence IntervalsOdds Ratiootorhinolaryngologic diseasesmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedSalvage TherapyAnalysis of VarianceAbsolute threshold of hearingmedicine.diagnostic_testbusiness.industryAudiogramHearing Loss SuddenMiddle AgedTreatment OutcomeSettore MED/31 - OtorinolaringoiatriaOtorhinolaryngologyCase-Control StudiesAnesthesiaAudiometry Pure-ToneFemaleAudiometrymedicine.symptombusinessFollow-Up Studiesmedicine.drugAmerican Journal of Otolaryngology
researchProduct

Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study.

2011

The aim of this study was to verify the efficacy and the safety of transtympanic dexamethasone to treat sudden sensorineural hearing loss as first and single drug method. Considering ethical implication of performing a mininvasive procedure on middle ear, we matched such proposed treatment with systemic prednisone administration that represents the widest adopted protocol. Randomized prospective study was conducted. The inclusion criterion was a sudden sensorineural hearing loss of at least 30 dB across three contiguous frequencies over a period of 24 h. Group A received transtympanic steroid injections; Group B received oral administration of steroids. 25 patients were treated with transty…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss SensorineuralAdministration OralInjections IntralesionalRisk AssessmentSeverity of Illness IndexDexamethasoneDrug Administration ScheduleAudiometryOral administrationPrednisoneSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedAnalysis of Variancemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGeneral MedicineHearing Loss SuddenMiddle AgedSurgeryCochlea Deafness Round window Sudden sensorineural hearing loss Steroid TranstympanicTreatment OutcomeOtorhinolaryngologyOtorhinolaryngologyFemaleNeurosurgeryAudiometrybusinessmedicine.drugFollow-Up Studies
researchProduct

Intratympanic Dexamethasone/Hyaluronic Acid Mix as an Adjunct to Intravenous Steroid and Vasoactive Treatment in Patients With Severe Idiopathic Sudd…

2011

To evaluate differences in effectiveness (hearing recovery rates) between idiopathic sudden sensorineural hearing loss (ISSNHL) patients treated with intravenous therapy alone and patients treated with a combination of intravenous and intratympanic therapy.Retrospective case review.Tertiary referral hospital center.Ninety-four patients with moderate ISSNHL treated with an intravenous steroid and vasoactive regimen (duration of therapy, 9 ± 2.76 d) and 76 patients with severe ISSNHL treated with a combination regimen of intravenous and intratympanic therapy (duration of therapy, 10 ± 2.71 d) were reviewed. In the latter patients' group, a series of 3 intratympanic injections of a dexamethaso…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss Sensorineuralmedicine.medical_treatmentIntratympanic dexamethasoneDexamethasoneInjectionsSteroidchemistry.chemical_compoundVasoactiveInternal medicineHyaluronic acidotorhinolaryngologic diseasesmedicineHumansIn patientHyaluronic AcidGlucocorticoidsRetrospective Studiesbusiness.industryHearing Loss SuddenSensory SystemsHearing recoveryTreatment OutcomeEndocrinologyOtorhinolaryngologychemistryIntravenous therapyAnesthesiaSudden sensorineural hearing lossInjections IntravenousAudiometry Pure-ToneFemaleSteroidsNeurology (clinical)businessOtology & Neurotology
researchProduct